Bello, Colombia

  • An Ophthalmic Safety Study in Patients With Breast Cancer

    This is a multicentre study assessing the ophthalmic safety in patients who are participating in a qualifying study. The study will include two cohorts of at least 60 individuals each. To be able to account for events associated with aging, worsening of pre-existing conditions, etc., ophthalmic study assessments will be performed in parallel in two cohorts at the same timepoints. The duration of the study assessment period will be approximately 12 months. Longer duration of the study would result in additional patient burden.

    Phase

    N/A

    Span

    122 weeks

    Sponsor

    AstraZeneca

    Leganes

    Recruiting

  • A Study of YL201 in Patients with Advanced Solid Tumors

    Phase

    1

    Span

    280 weeks

    Sponsor

    MediLink Therapeutics (Suzhou) Co., Ltd.

    Leganes, Madrid

    Recruiting

1-2 of 2